IRD

AS OF

Jan 14 closing price

Price

$2.17

Change

+$0.03 (+1.40%)

Capitalization

151.03M

Intraday BUY SELL Signals

OUR PRODUCTS

MOBILE APPS

GENERAL INFO

Help

IRD

Stock ticker: NASDAQ

PRICE

CHANGE

CAPITALIZATION

Opus Genetics (IRD) Ownership - Who owns Opus Genetics?

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders... Show more

Get AI intraday signals

#MovingAverage #Momentum #MACD #Pattern #RSI #Stochastic #Aroon #Bollinger

Details

Group

Domestic Stock Funds

Fundamentals

IRD

Capitalization

151M

P/E Ratio

N/A

Risk (Beta)

0.88

Dividend Yield

N/A

Total Cash

30.8M

Total Cash/Share

0.45

Total Debt

1.07M

Total Debt/Equity

N/A

Projected Growth (PEG Ratio)

N/A

Revenue/Share (as % of the share price)

0.29%

Revenue

14.6M

ROE

N/A

Book Value

5.97M

P/B Ratio

25.32

Cash Flow

N/A

Earnings

-1.86

Average Daily Volume YTD

N/A

Common Shares Outstanding - Security Level

Current Ratio

1.23

Current Revenue Per Employee

171055.56

Dividends Per Share - Security

N/A

EBITDA

-68.09M

Float

N/A

Float - Current

N/A

Gross Income Margin

N/A

Revenue To Assets

-178.28

Shares Held By Institutions

32.7M

Shares Outstanding - Current

69M

Total Liabilities

30.2M

Total Volume MTD

N/A

Value

-1

Gain YTD

7.960

View a ticker or compare two or three

Compare

IRD

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.

View AI-Driven Trading for IRD

A.I. Advisor

published General Information

General Information

a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics

Industry Biotechnology

Profile

Fundamentals

Details